The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Colchicine Effective for Acute Pericarditis

Colchicine Effective for Acute Pericarditis

October 25, 2013 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients with acute pericarditis who are treated with colchicine in combination with a traditional antiinflammatory therapy experience a significantly reduced rate of incessant or recurrent pericarditis.

You Might Also Like
  • Letters: A Word of Caution on Colchicine Study
  • FDA Enforcement Against Injectable Colchicine
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
Also By This Author
  • Rat Model of Arthritis Sheds Light on How Disease Affects Bone

Massimo Imazio, MD, of Maria Vittoria Hospital in Turin, Italy, and colleagues published the results of the Investigation on Colchicine for Acute Pericarditis (ICAP) trial in The New England Journal of Medicine.1 The multicenter, double-blind trial included adults with idiopathic/viral pericarditis, postpericardiotomy syndromes, and pericarditis related to a systemic inflammatory disease. Patients were included with their first episode of acute pericarditis, but excluded if they had elevated levels of aminotransferases, creatinine, or troponin.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients were randomly assigned to receive three months of traditional antiinflammatory therapy plus either colchicine (0.5 mg twice daily for patients weighing >70 kg or 0.5 mg once daily for patients weighing ≤70 kg) or placebo. The majority of the patients in the study were treated with aspirin and a small percentage received ibuprofen.

The primary study outcome was incessant or recurrent pericarditis. Patients were followed for an average of 22 months (minimum 18 months). In the colchicine group, 16.7% of patients were diagnosed with incessant or recurrent pericarditis, whereas 37.5% of patients in the control group received the diagnosis (p <0.001). This translated into a relative risk reduction of 0.56 in the colchicine group and a number needed to treat of four.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The European Society of Cardiology guidelines on pericardial disease recommend colchicine as a first-line treatment for recurrent pericarditis (class I indication). In contrast, a class IIa indication was given for the use of colchicine to treat an initial attack of acute pericarditis. The difference in recommendation reflected a lack of clinical trials specific for an initial attack of acute pericarditis.

“Of note, colchicine is not approved for the prevention of recurrent pericarditis in North America or Europe, and its use as such is off label,” wrote Dr. Imazio in an e-mail to The Rheumatologist.

Current guidelines recommend that colchicine be dosed at 2 mg/day for one to two days followed by a maintenance dose of 1 mg/day. The optimal treatment dose for colchicine has not yet been determined, however. Lower dosages (such as those described in this study) may be just as effective as the higher dosages and have the added benefit of improved patient compliance. Dr. Imazio speculated that longer treatments (>3 months) may also result in greater benefits.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“Most treatments are empirical in the setting of pericarditis. At present, colchicine is the most studied drug in this field, and we have enough evidence (an open label randomized trial, the COPE [Colchicine for Acute Pericarditis] trial, and a multicenter double-blind randomized trial [the present ICAP study]), in my view, to support its use in acute pericarditis (first episode) as well as for the first recurrence of pericarditis after the index attack as supported by the previously published CORP [Colchicine for Recurrent Pericarditis] trial,” wrote Dr. Imazio in an e-mail.

Pages: 1 2 | Single Page

Filed Under: Conditions, Crystal Arthritis, Research Reviews Tagged With: Colchicine, Pericarditis, Systemic inflammatory disease

You Might Also Like:
  • Letters: A Word of Caution on Colchicine Study
  • FDA Enforcement Against Injectable Colchicine
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
  • Generic Colchicine Approved for Gout Prophylaxis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)